Novel drug - dinutuximab for high-risk neuroblastoma
Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah |
| _version_ | 1818668674126446592 |
|---|---|
| author | Supriya Kushwah Ashutosh Kumar S Shabnam |
| author_facet | Supriya Kushwah Ashutosh Kumar S Shabnam |
| author_sort | Supriya Kushwah |
| collection | DOAJ |
| description | Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or interleukin-2, have been recently approved by Food and Drug Administration for the treatment of high-risk neuroblastoma. Dinutuximab binds to the glycolipid GD2 present on neuroblastoma cells and cells of neuroectodermal origin and enhances cell lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. |
| first_indexed | 2024-12-17T06:40:04Z |
| format | Article |
| id | doaj.art-382b5bc22f4b4b1ba5224bb9ea443aa7 |
| institution | Directory Open Access Journal |
| issn | 0976-0016 2213-3682 |
| language | English |
| last_indexed | 2024-12-17T06:40:04Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Apollo Medicine |
| spelling | doaj.art-382b5bc22f4b4b1ba5224bb9ea443aa72022-12-21T21:59:53ZengWolters Kluwer Medknow PublicationsApollo Medicine0976-00162213-36822018-01-0115313213410.4103/am.am_14_17Novel drug - dinutuximab for high-risk neuroblastomaSupriya KushwahAshutosh KumarS ShabnamNeuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or interleukin-2, have been recently approved by Food and Drug Administration for the treatment of high-risk neuroblastoma. Dinutuximab binds to the glycolipid GD2 present on neuroblastoma cells and cells of neuroectodermal origin and enhances cell lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwahantibody-dependent cell-mediated cytotoxicityanti-gd2 monoclonal antibodiesdinutuximabextracranial tumorneuroblastoma |
| spellingShingle | Supriya Kushwah Ashutosh Kumar S Shabnam Novel drug - dinutuximab for high-risk neuroblastoma Apollo Medicine antibody-dependent cell-mediated cytotoxicity anti-gd2 monoclonal antibodies dinutuximab extracranial tumor neuroblastoma |
| title | Novel drug - dinutuximab for high-risk neuroblastoma |
| title_full | Novel drug - dinutuximab for high-risk neuroblastoma |
| title_fullStr | Novel drug - dinutuximab for high-risk neuroblastoma |
| title_full_unstemmed | Novel drug - dinutuximab for high-risk neuroblastoma |
| title_short | Novel drug - dinutuximab for high-risk neuroblastoma |
| title_sort | novel drug dinutuximab for high risk neuroblastoma |
| topic | antibody-dependent cell-mediated cytotoxicity anti-gd2 monoclonal antibodies dinutuximab extracranial tumor neuroblastoma |
| url | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah |
| work_keys_str_mv | AT supriyakushwah noveldrugdinutuximabforhighriskneuroblastoma AT ashutoshkumar noveldrugdinutuximabforhighriskneuroblastoma AT sshabnam noveldrugdinutuximabforhighriskneuroblastoma |